# US 9,040,081 B2 · Use of lipid containing particles comprising Quillaja saponins for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,040,081 B2
- Document ID: US9040081B2
- Status: Granted
- Kind: B2
- Application number: 12/515,684
- Filed: 2007-11-20
- Published: 2010-05-13
- Granted: 2015-05-26
- Earliest claimed: 2006-11-20
- Assignees: Duecom
- Applicants: Kefei Hu; Bror Morein
- Inventors: Kefei Hu; Bror Morein
- Web page: https://patentgrep.com/patent/US9040081B2

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/572: {cytotoxic response}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of lipid containing particles, such as liposomes, iscom and/or iscom matrix and posintros, comprising at least one lipid and at least one saponin for the preparation of a pharmaceutical for the treatment of cancer. The saponins are preferably from Quillaja Saponaria Molina. Further, the particles are also delivery systems for one or several compounds for cancer treatment with complementary mechanisms. More, the invention discloses kit of parts comprising at least two parts, wherein one part comprising at least one saponin fraction which is hydrophobic having a killing effect on cancer cell; and the other part comprising at least one saponin fraction which is comparatively hydrophilic, stimulating and modulating the immune response.

## Claims

### Claim 1

A method for the treatment of cancer wherein an iscom matrix particle comprising at least one lipid selected from cholesterol and phospholipid and at least one saponin, chosen from fraction A and fraction C from Quillaja saponaria Molina or a sub fraction thereof, which particle does not contain cancer antigens, is administered to an individual in need of cancer treatment.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the iscom matrix particle further comprises one or more saponins chosen from fraction B, fractions QA 1-22 of Quillaja saponaria Molina, Spicoside and Q VAC.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or 2, wherein the iscom matrix particles contain at least two different saponin fractions in one and the same lipid containing particle.

### Claim 4 (depends on 1, 2)

The method according to claim 1 or 2, wherein the iscom matrix particles contain at least two different saponin fractions, whereby one of the at least two different saponin fractions is complex bound in one isco matrix particle and the other one (the other ones) of the at least two different saponin fractions is (are) complex bound in another (other) physical different lipid containing particle(s).

### Claim 5 (depends on 1)

The method according to claim 1, wherein further cancer treating compounds are used together with the lipid containing particles.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the cancer treating compounds are chosen from platinum coordination compounds, taxane compounds, camptothecin compounds, anti-tumor vinca alkaloids, anti-tumor nucleoside derivatives, nitrogen mustard or nitrosourea alkylating agents, anti-tumor anthracycline derivatives, trastzumab and anti-tumor podophyllotoxin derivatives, Quila A and sub fragments thereof.

### Claim 7 (depends on 1)

The method according to claim 1, wherein further adjuvants are integrated into the iscom matrix particles, coupled on to the particles or mixed with the iscom matrix particles.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the lipid containing particle comprises cancer targeting molecules.